Table 2.
Pulmonary function phenotypes among individuals with pulmonary involvement
| Restriction (n = 149) | Obstruction (n = 71) |
Combined (n = 50) |
Isolated DlCO (n = 46) |
Normal (n = 246) |
P Value | |
|---|---|---|---|---|---|---|
| Race n (%) | ||||||
| Black (n = 312) | 127 (41) | 28 (9) | 38 (12) | 37 (12) | 82 (26) | <0.001 |
| White (n = 250) | 22 (9) | 43 (17) | 12 (5) | 9 (4) | 164 (66) | |
| Sex n (%) | ||||||
| Female (n = 355) | 105 (30) | 32 (9) | 30 (8) | 30 (8) | 158 (45) | 0.008 |
| Male (n = 207) | 44 (21) | 39 (19) | 20 (10) | 16 (8) | 88 (43) | |
| Tobacco use n (%) | ||||||
| No use (n = 320) | 94 (29) | 34 (11) | 22 (7) | 19 (6) | 151 (47) | 0.001 |
| Past use (n = 184) | 39 (21) | 29 (16) | 18 (10) | 18 (10) | 80 (44) | |
| Current use (n = 45) | 10 (22) | 8 (18) | 9 (20) | 8 (18) | 10 (22) | |
| Organ Involvement n (%) | ||||||
| 1 organ (n = 197) | 52 (26) | 25 (13) | 19 (10) | 9 (5) | 92 (47) | 0.077 |
| 2–4 organs (n = 342) | 88 (26) | 44 (13) | 31 (9) | 31 (9) | 147 (43) | |
| >4 organs (n = 23) | 9 (39) | 2 (9) | 0 (0) | 5 (22) | 7 (30) | |
| Chest imaging n (%) | ||||||
| Normal (n = 76) | 12 (16) | 5 (7) | 6 (8) | 11 (15) | 42 (55) | <0.001 |
| Lymph node involvement only (n = 59) | 11 (19) | 4 (7) | 1 (2) | 5 (8) | 38 (64) | |
| Lymph node and parenchymal involvement (n = 153) | 46 (30) | 22 (14) | 7 (5) | 12 (8) | 66 (43) | |
| Parenchymal involvement only (n = 121) | 30 (25) | 21 (17) | 12 (10) | 8 (7) | 50 (41) | |
| Fibrocystic disease (n = 22) | 11 (50) | 3 (14) | 5 (23) | 0 (0) | 3 (14) | |
| Age at testing (yr), median (IQR) | 50 (44–57) | 49 (42–57) | 48 (43–55) | 52 (44–61) | 52 (46–61) | 0.596 |
| Disease duration (yr from diagnosis), median (IQR) | 6 (2–15) | 4 (1–12) | 10 (2–20) | 6 (1–18) | 3 (1–9) | 0.037 |
Definition of abbreviations: DlCO = diffusing capacity of the lung for carbon monoxide; IQR = interquartile. range.